Cancer Family
Eye Neoplasm
CI-CAN-00000017Explore in graph →
Non-malignant86 active trials2 approved drugs19 evidence items
Loading cancer entity…
Loading cancer entity…
Cancer Family
CI-CAN-00000017Explore in graph →
Clinical trials
463 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT05282901 | Efficacy and Safety of Pembrolizumab in Combination With Lenvatinib in Metastatic Uveal MElanoma Patients (PLUME)(PLUME) | completed | Phase 2 | 51 | Institut CurieOTHER | 1 | Jul 28, 2026 | clinicaltrials |
| NCT03472586 | Ipilimumab and Nivolumab With Immunoembolization in Treating Participants With Metastatic Uveal Melanoma in the Liver | completed | Phase 2 | 14 | Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson UniversityOTHER | 1 |
| Jul 7, 2026 |
| clinicaltrials |
| NCT05187884 | Neoadjuvant/Adjuvant Trial of Darovasertib in Ocular Melanoma(NADOM) | completed | Phase 2 | 15 | St Vincent's Hospital, SydneyOTHER | 1 | Apr 23, 2026 | clinicaltrials |
| NCT03070392 | Safety and Efficacy of IMCgp100 Versus Investigator Choice in Advanced Uveal Melanoma | completed | Phase 2 | 378 | Immunocore LtdINDUSTRY | 14 | Mar 17, 2026 | clinicaltrials |
| NCT02213913 | Lenalidomide and Combination Chemotherapy (DA-EPOCH-R) in Treating Patients With MYC-Associated B-Cell Lymphomas | completed | Phase 1 / Phase 2 | 55 | University of ChicagoOTHER | 1 | Mar 11, 2026 | clinicaltrials |
| NCT02517736 | Study Multicentre Evaluating the Effectiveness and Toxicity Sorafenib (Nexavar®) in Adult Patients With Uveal Melanoma and Metastatic Dissemination(O-Mel-Sora) | completed | Phase 2 | 32 | University Hospital, CaenOTHER | 1 | Feb 17, 2026 | clinicaltrials |
| NCT04552223 | Nivolumab Plus Relatlimab in Patients With Metastatic Uveal Melanoma | completed | Phase 2 | 27 | Jose Lutzky, MDOTHER | 1 | Feb 11, 2026 | clinicaltrials |
| NCT01473004 | SIR-Spheres® 90Y Microspheres Treatment of Uveal Melanoma Metastasized to Liver | completed | Phase 2 | 48 | Thomas Jefferson UniversityOTHER | 1 | Nov 14, 2025 | clinicaltrials |
| NCT00661622 | Halt Growth of Liver Tumors From Uveal Melanoma With Closure of Liver Artery Following Injection of GM-CSF | completed | Phase 2 | 53 | Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson UniversityOTHER | 1 | May 16, 2025 | clinicaltrials |
| NCT01355120 | THE IPI - Trial in Advanced Melanoma: Melanoma Patients With Advanced Disease(DeCOG) | completed | Phase 2 | 171 | Prof. Dr. med. Dirk SchadendorfOTHER | 1 | Apr 9, 2025 | clinicaltrials |
| NCT04417530 | Phase 2 Trial to Evaluate Belzupacap Sarotalocan (AU-011) Via Suprachoroidal Administration in Subjects With Primary Indeterminate Lesions and Small Choroidal Melanoma | completed | Phase 2 | 22 | Aura BiosciencesINDUSTRY | 1 | Mar 3, 2025 | clinicaltrials |
| NCT02936388 | Transarterial Radioembolisation in Comparison to Transarterial Chemoembolisation in Uveal Melanoma Liver Metastasis(SirTac) | completed | Phase 2 | 108 | Charite University, Berlin, GermanyOTHER | 1 | Jan 24, 2025 | clinicaltrials |
| NCT04364230 | Melanoma Vaccine Against Neoantigen and Shared Antigens by CD40 Activation and TLR Agonists In Patients With Melanoma (Including Ocular Melanoma)(Mel66) | completed | Phase 1 / Phase 2 | 22 | Craig L Slingluff, JrOTHER | 1 | Jul 16, 2024 | clinicaltrials |
| NCT01585194 | Nivolumab and Ipilimumab in Treating Patients With Metastatic Uveal Melanoma | completed | Phase 2 | 67 | M.D. Anderson Cancer CenterOTHER | 1 | Jul 9, 2024 | clinicaltrials |
| NCT02519322 | Neoadjuvant and Adjuvant Checkpoint Blockade | completed | Phase 2 | 53 | M.D. Anderson Cancer CenterOTHER | 1 | Apr 5, 2024 | clinicaltrials |
| NCT00445965 | Iodine I 131 Monoclonal Antibody 3F8 in Treating Patients With Central Nervous System Cancer or Leptomeningeal Cancer | completed | Phase 2 | 78 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Apr 4, 2024 | clinicaltrials |
| NCT00020475 | Vaccine Therapy in Treating Patients With Metastatic Melanoma of the Eye | completed | Phase 2 | — | National Cancer Institute (NCI)NIH | 1 | Mar 4, 2024 | clinicaltrials |
| NCT03052127 | Study in Subjects With Small Primary Choroidal Melanoma | completed | Phase 1 / Phase 2 | 57 | Aura BiosciencesINDUSTRY | 1 | Feb 1, 2024 | clinicaltrials |
| NCT02697630 | Efficacy Study of Pembrolizumab With Entinostat to Treat Metastatic Melanoma of the Eye(PEMDAC) | completed | Phase 2 | 29 | Vastra Gotaland RegionOTHER_GOV | 1 | Dec 8, 2023 | clinicaltrials |
| NCT02223819 | Crizotinib in High-Risk Uveal Melanoma Following Definitive Therapy | completed | Phase 2 | 34 | Columbia UniversityOTHER | 1 | Dec 6, 2023 | clinicaltrials |
| NCT03207347 | A Trial of Niraparib in BAP1 and Other DNA Damage Response (DDR) Deficient Neoplasms (UF-STO-ETI-001) | completed | Phase 2 | 37 | University of FloridaOTHER | 1 | Sep 15, 2023 | clinicaltrials |
| NCT02570308 | A Study of the Intra-Patient Escalation Dosing Regimen With IMCgp100 in Patients With Advanced Uveal Melanoma | completed | Phase 1 / Phase 2 | 146 | Immunocore LtdINDUSTRY | 5 | Mar 21, 2023 | clinicaltrials |
| NCT01835145 | Cabozantinib-S-Malate Compared With Temozolomide or Dacarbazine in Treating Patients With Metastatic Melanoma of the Eye That Cannot Be Removed by Surgery | completed | Phase 2 | 47 | National Cancer Institute (NCI)NIH | 2 | Aug 4, 2022 | clinicaltrials |
| NCT00084656 | Monoclonal Antibody Therapy and Vaccine Therapy in Treating Patients With Resected Stage III or Stage IV Melanoma | completed | Phase 2 | 77 | Bristol-Myers SquibbINDUSTRY | 1 | Apr 14, 2022 | clinicaltrials |
| NCT02542514 | Study of Ibrutinib in Patients With Relapsed or Refractory Primary Central Nervous Lymphoma or Intraocular Lymphoma(iLOC) | completed | Phase 2 | 52 | The Lymphoma Academic Research OrganisationOTHER | 1 | Apr 14, 2022 | clinicaltrials |
| NCT02626962 | Trial of Nivolumab in Combination With Ipilimumab in Subjects With Previously Untreated Metastatic Uveal Melanoma(GEM1402) | completed | Phase 2 | 52 | Grupo Español Multidisciplinar de MelanomaOTHER | 1 | Mar 22, 2022 | clinicaltrials |
| NCT02129075 | A Vaccine (CDX-1401) With or Without a Biologic Drug (CDX-301) for the Treatment of Patients With Stage IIB-IV Melanoma | completed | Phase 2 | 60 | National Cancer Institute (NCI)NIH | 1 | Nov 16, 2021 | clinicaltrials |
| NCT01258998 | Study of Akt Inhibitor MK2206 in Patients With Relapsed Lymphoma | completed | Phase 2 | 60 | National Cancer Institute (NCI)NIH | 1 | Nov 4, 2020 | clinicaltrials |
| NCT02363283 | Glembatumumab Vedotin in Treating Patients With Metastatic or Locally Recurrent Uveal Melanoma | completed | Phase 2 | 37 | National Cancer Institute (NCI)NIH | 1 | Aug 21, 2020 | clinicaltrials |
| NCT00179920 | Chemotherapy Treatment for Children With Intraocular Germ-Line Retinoblastoma | completed | Phase 2 | 30 | Ann & Robert H Lurie Children's Hospital of ChicagoOTHER | 1 | Aug 5, 2020 | clinicaltrials |
| NCT01413191 | Cixutumumab in Treating Patients With Metastatic Melanoma of the Eye | completed | Phase 2 | 18 | National Cancer Institute (NCI)NIH | 1 | Feb 19, 2020 | clinicaltrials |
| NCT00006251 | Fludarabine Phosphate, Low-Dose Total-Body Irradiation, and Donor Stem Cell Transplant Followed by Cyclosporine, Mycophenolate Mofetil, Donor Lymphocyte Infusion in Treating Patients With Hematopoietic Cancer | completed | Phase 1 / Phase 2 | 21 | Fred Hutchinson Cancer CenterOTHER | 2 | Jan 21, 2020 | clinicaltrials |
| NCT02158520 | Nab-Paclitaxel and Bevacizumab or Ipilimumab as First-Line Therapy in Treating Patients With Stage IV Melanoma That Cannot Be Removed by Surgery | completed | Phase 2 | 24 | Academic and Community Cancer Research UnitedOTHER | 1 | Jan 21, 2020 | clinicaltrials |
| NCT01326702 | Veliparib, Bendamustine Hydrochloride, and Rituximab in Treating Patients With Relapsed or Refractory Lymphoma, Multiple Myeloma, or Solid Tumors | completed | Phase 1 / Phase 2 | 43 | National Cancer Institute (NCI)NIH | 1 | Dec 16, 2019 | clinicaltrials |
| NCT01551459 | A Phase II Study of Sunitinib Versus Dacarbazine in the Treatment of Patients With Metastatic Uveal Melanoma(SUAVE) | completed | Phase 2 | 124 | The Clatterbridge Cancer Centre NHS Foundation TrustOTHER | 1 | Oct 29, 2019 | clinicaltrials |
| NCT01839916 | Donor T Cells After Donor Stem Cell Transplant in Treating Patients With Hematologic Malignancies | completed | Phase 2 | 77 | University of ChicagoOTHER | 1 | Aug 7, 2019 | clinicaltrials |
| NCT01100528 | Dacarbazine and Recombinant Interferon Alfa-2b in Treating Patients With Primary Uveal Melanoma With Genetic Imbalance | completed | Phase 2 | 38 | Case Comprehensive Cancer CenterOTHER | 1 | Feb 26, 2019 | clinicaltrials |
| NCT00121225 | Vorinostat in Treating Patients With Metastatic or Unresectable Melanoma | completed | Phase 2 | 32 | National Cancer Institute (NCI)NIH | 2 | Jan 29, 2019 | clinicaltrials |
| NCT01200238 | STA-9090(Ganetespib) in Metastatic Ocular Melanoma | completed | Phase 2 | 17 | Dana-Farber Cancer InstituteOTHER | 1 | Oct 18, 2018 | clinicaltrials |
| NCT01273766 | Deferasirox in Treating Iron Overload Caused By Blood Transfusions in Patients With Hematologic Malignancies | completed | Phase 2 | 16 | Wake Forest University Health SciencesOTHER | 1 | Sep 7, 2018 | clinicaltrials |
| NCT00243061 | AZD2171 in Treating Patients With Recurrent or Stage IV Melanoma | completed | Phase 2 | 24 | National Cancer Institute (NCI)NIH | 1 | Aug 27, 2018 | clinicaltrials |
| NCT01154452 | Vismodegib and Gamma-Secretase/Notch Signalling Pathway Inhibitor RO4929097 in Treating Patients With Advanced or Metastatic Sarcoma | completed | Phase 1 / Phase 2 | 78 | National Cancer Institute (NCI)NIH | 1 | Aug 15, 2018 | clinicaltrials |
| NCT01789255 | Vorinostat, Tacrolimus, and Methotrexate in Preventing GVHD After Stem Cell Transplant in Patients With Hematological Malignancies | completed | Phase 2 | 12 | National Cancer Institute (NCI)NIH | 1 | Jul 24, 2018 | clinicaltrials |
| NCT01961115 | Epacadostat and Vaccine Therapy in Treating Patients With Stage III-IV Melanoma | completed | Phase 2 | 11 | Fred Hutchinson Cancer CenterOTHER | 1 | Jun 8, 2018 | clinicaltrials |
| NCT00450255 | VEGF Trap in Treating Patients With Recurrent Stage III or Stage IV Melanoma That Cannot Be Removed by Surgery | completed | Phase 2 | 41 | National Cancer Institute (NCI)NIH | 1 | May 24, 2018 | clinicaltrials |
| NCT00867529 | Rituximab in Treating Patients Undergoing Donor Peripheral Blood Stem Cell Transplant for Relapsed or Refractory B-cell Lymphoma | completed | Phase 2 | 63 | Fred Hutchinson Cancer CenterOTHER | 1 | Jan 2, 2018 | clinicaltrials |
| NCT01034787 | Study of AntiCTLA4 in Patients With Unresectable or Metastatic Uveal Melanoma | completed | Phase 2 | 11 | AHS Cancer Control AlbertaOTHER | 1 | Oct 27, 2017 | clinicaltrials |
| NCT01252251 | RAD001 (Everolimus) and Pasireotide (SOM230) LAR in Patients With Advanced Uveal Melanoma | completed | Phase 2 | 14 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Aug 1, 2017 | clinicaltrials |
| NCT01143402 | Temozolomide or Selumetinib in Treating Patients With Metastatic Melanoma of the Eye | completed | Phase 2 | 120 | National Cancer Institute (NCI)NIH | 2 | Jul 26, 2017 | clinicaltrials |
Data updated 22 days agoSource updated Jul 28, 2026source: clinicaltrials